An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants
Completed
Forest Laboratories
N/A
2006-06-01
This study is designed to evaluate anxious patients who are only partially responsive to
typical SSRI or SNRI anti-anxiety medication therapy. Patients who are less than 50%
anxiety-alleviated on their SSRI medication will be asked to join the study and be placed on
Acamprosate as well. This type of add-on therapy is common in outpatient psychiatric care.
This is a rater-blinded, patient open-label, non-placebo prospective study, where all
subjects will receive Acamprosate for 8 weeks. This study would be the first to date in this
treatment-resistant patient population, as the investigators will utilize the a comprehensive
set of rating scales in order to best categorize patient responses in regards to anxiety,
co-occurring depression, sleep disorders, alcohol use, and social functioning with this drug.
This study may be pivotal to the initiation of future double-blind, placebo-controlled
studies for this agent
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
